Stay updated on Apremilast-Dupilumab Combo in Eczema Clinical Trial

Sign up to get notified when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Apremilast-Dupilumab Combo in Eczema Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.4.2. The funding-status notice has been removed (the previous Revision: v3.4.1 was deleted).
    Difference
    0.5%
    Check dated 2026-02-11T09:25:11.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a funding-status notice at the top of the page about potential data currency issues and a Revision banner showing v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-04T06:17:59.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a glossary display option and updated labeling for QC-related items (Last Update Submitted that Met QC Criteria; No FEAR Act Data) with a revision notice (Revision: v3.4.0), replacing the previous variants (Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T03:51:37.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision metadata updated from v3.3.3 to v3.3.4 in the page footer. No changes to the study content are apparent.
    Difference
    0.1%
    Check dated 2026-01-14T01:32:45.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Added a dedicated Locations section featuring Massachusetts (Boston, MA) as a study location and removed the prior Massachusetts Locations entry; the page revision was updated from v3.3.2 to v3.3.3, and the HHS Vulnerability Disclosure link in the footer was removed.
    Difference
    0.2%
    Check dated 2025-12-23T09:13:44.000Z thumbnail image
  7. Check
    92 days ago
    Change Detected
    Summary
    Revision: v3.3.2 replaces v3.2.0 on the page. It is a minor site update and does not modify study details or user actions.
    Difference
    0.1%
    Check dated 2025-11-24T18:20:14.000Z thumbnail image

Stay in the know with updates to Apremilast-Dupilumab Combo in Eczema Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.